Nanologica AB is a biotechnology company based in Södertälje that focuses on enhancing the accessibility of medicines for diabetes and obesity. The company is engaged in the development of innovative pharmaceutical products, with a particular specialization in NLAB Saga® silica, which is utilized for preparative chromatography. This technology is aimed at improving the efficiency and effectiveness of drug formulation processes.
The company has recently secured a significant order valued at SEK 1.5 million for a new product, alongside another order of approximately SEK 1 million from China. These developments reflect Nanologica's commitment to advancing research and development in the field of biotechnology, with an emphasis on improving patient outcomes. By striving to provide better and more affordable medicines, Nanologica aims to serve a larger patient population with effective treatment options.